Renate Pichler1, Wegene Borena2, Georg Schäfer3, Claudia Manzl3, Zoran Culig1, Sebastian List1, Sabrina Neururer4, Dorothee Von Laer2, Isabel Heidegger1, Helmut Klocker1, Wolfgang Horninger1, Hannes Steiner1, Andrea Brunner5. 1. Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. 2. Section of Virology, Department of Hygiene, Microbiology and Social Medicine, Innsbruck, Austria. 3. Division of General Pathology, Department of Pathology, Medical University Innsbruck, Innsbruck, Austria. 4. Department of Medical Statistics, Informatics and Health Economics, Müllerstrasse 44A-6020, Innsbruck, Austria. 5. Division of General Pathology, Department of Pathology, Medical University Innsbruck, Innsbruck, Austria. Andrea.Brunner@i-med.ac.at.
Abstract
PURPOSE: To clarify the role of human papillomavirus (HPV) in non-muscle invasive bladder cancer, HPV-DNA was scrutinized in formalin-fixed, paraffin-embedded (FFPE) bladder cancer tissue using single-step PCR (HPV L1) for HPV detection, followed by reverse line blot (RLB) for genotyping. METHODS: A total of 186 patients who underwent transurethral resection of the bladder due to primary, non-muscle invasive bladder cancer from 2006 to 2009 were reviewed. A positive control group of 22 cervical tissues with cervical carcinoma was included. RESULTS: Histology confirmed urothelial carcinoma in all patients: primary CIS, pTa, pT1 and pTa + pT1 in 14 (7.5 %), 134 (72 %), 36 (19.4 %) and two (1.1 %) patients, respectively. A total of 119 (63.9 %) of them were classified as low-risk, while 67 (36.1 %) were high-risk cancers. Tumor recurrence and progression (≥pT2) were seen in 79 and 11 patients (mean follow-up 45 months). The presence of HPV-DNA by single-step PCR was detected in four (2.2 %) patients. HPV 16 and HPV 6 were positive in two (1.1 %) and one (0.6 %) patient, respectively In one case, no HPV genotype listed on the RLB assay could be identified. In the control group, the HPV infection rate was 100 %: HPV 16 in 12 (54.6 %) patients, HPV 16/18 in four (18.3 %) patients, HPV 18 in two (9.1 %) patients, HPV 16/45 in one patient (4.5 %), HPV 18/33 in one (4.5 %) patient, HPV 16/33 in one (4.5 %) patient and HPV 33 in one (4.5 %) patient. CONCLUSIONS: Our study demonstrates low prevalence of HPV infection in FFPE bladder cancer tissue, arguing against the etiological role of HPV in non-muscle urothelial carcinogenesis.
PURPOSE: To clarify the role of human papillomavirus (HPV) in non-muscle invasive bladder cancer, HPV-DNA was scrutinized in formalin-fixed, paraffin-embedded (FFPE) bladder cancer tissue using single-step PCR (HPV L1) for HPV detection, followed by reverse line blot (RLB) for genotyping. METHODS: A total of 186 patients who underwent transurethral resection of the bladder due to primary, non-muscle invasive bladder cancer from 2006 to 2009 were reviewed. A positive control group of 22 cervical tissues with cervical carcinoma was included. RESULTS: Histology confirmed urothelial carcinoma in all patients: primary CIS, pTa, pT1 and pTa + pT1 in 14 (7.5 %), 134 (72 %), 36 (19.4 %) and two (1.1 %) patients, respectively. A total of 119 (63.9 %) of them were classified as low-risk, while 67 (36.1 %) were high-risk cancers. Tumor recurrence and progression (≥pT2) were seen in 79 and 11 patients (mean follow-up 45 months). The presence of HPV-DNA by single-step PCR was detected in four (2.2 %) patients. HPV 16 and HPV 6 were positive in two (1.1 %) and one (0.6 %) patient, respectively In one case, no HPV genotype listed on the RLB assay could be identified. In the control group, the HPV infection rate was 100 %: HPV 16 in 12 (54.6 %) patients, HPV 16/18 in four (18.3 %) patients, HPV 18 in two (9.1 %) patients, HPV 16/45 in one patient (4.5 %), HPV 18/33 in one (4.5 %) patient, HPV 16/33 in one (4.5 %) patient and HPV 33 in one (4.5 %) patient. CONCLUSIONS: Our study demonstrates low prevalence of HPV infection in FFPE bladder cancer tissue, arguing against the etiological role of HPV in non-muscle urothelial carcinogenesis.
Entities:
Keywords:
Bladder cancer; Carcinogenesis; Human papillomavirus; Hybridization; Infection; PCR
Authors: Sung Han Kim; Jae Young Joung; Jinsoo Chung; Weon Seo Park; Kang Hyun Lee; Ho Kyung Seo Journal: PLoS One Date: 2014-03-27 Impact factor: 3.240
Authors: Riley E Alexander; Sean R Williamson; Justin Richey; Antonio Lopez-Beltran; Rodolfo Montironi; Darrell D Davidson; Muhammad T Idrees; Carol L Jones; Shaobo Zhang; Lisha Wang; Qiu Rao; Jose A Pedrosa; Hristos Z Kaimakliotis; M Francesca Monn; Michael O Koch; Liang Cheng Journal: PLoS One Date: 2014-04-21 Impact factor: 3.240
Authors: Isabel Heidegger; Renate Pichler; Barbara Müller; Helmut Klocker; David Oswald; Bernhard Haid; Bettina Zelger; Wolfgang Horninger; Josef Oswald Journal: World J Urol Date: 2013-10-22 Impact factor: 4.226
Authors: Julie Steinestel; Marcus V Cronauer; Johannes Müller; Andreas Al Ghazal; Peter Skowronek; Annette Arndt; Klaus Kraft; Mark Schrader; Andres J Schrader; Konrad Steinestel Journal: PLoS One Date: 2013-05-28 Impact factor: 3.240
Authors: Sergei Guma; Remegio Maglantay; Ryan Lau; Rosemary Wieczorek; Jonathan Melamed; Fang-Ming Deng; Ming Zhou; Danil Makarov; Peng Lee; Matthew R Pincus; Zhi-Heng Pei Journal: Am J Clin Exp Urol Date: 2016-01-28
Authors: Sebastian C Schmid; Leonore Thümer; Tibor Schuster; Thomas Horn; Florian Kurtz; Julia Slotta-Huspenina; Judith Seebach; Michael Straub; Tobias Maurer; Michael Autenrieth; Hubert Kübler; Margitta Retz; Ulrike Protzer; Jürgen E Gschwend; Dieter Hoffmann Journal: Infect Agent Cancer Date: 2015-09-21 Impact factor: 2.965
Authors: Narcisa Muresu; Biagio Di Lorenzo; Laura Saderi; Illari Sechi; Arcadia Del Rio; Andrea Piana; Giovanni Sotgiu Journal: Diagnostics (Basel) Date: 2022-07-20